81744-03-8

Basic information

• Product Name: 2-(2-hydroxyphenyl)-1,2-benzoselenazol-3(2H)-one
• CAS NO: 81744-03-8
• Molecular Formula: C₁₃H₉NO₂Se
• Molecular Weight: 290.1761
• Mol File: 81744-03-8.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 441.4°C at 760 mmHg
• Flash Point: 220.8°C
• Vapor Pressure: 2.1E-08mmHg at 25°C
• CAS DataBase Reference: 2-(2-hydroxyphenyl)-1,2-benzoselenazol-3(2H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2-hydroxyphenyl)-1,2-benzoselenazol-3(2H)-one(81744-03-8)
• EPA Substance Registry System: 2-(2-hydroxyphenyl)-1,2-benzoselenazol-3(2H)-one(81744-03-8)

Safety Data

• Hazardous Substances Data: 81744-03-8(Hazardous Substances Data)

Upstream product

• 1441-85-6 2-(chloroseleno)benzoyl chloride 
• 95-55-6 2-amino-phenol 
• 6512-83-0 2,2'-diselanediyl-di-benzoic acid 
• 118-92-3 anthranilic acid 
• 76356-95-1 2-hydroaniline 

Relevant articles and documents

Reaction of bis[(2-chlorocarbonyl)phenyl] diselenide with phenols, aminophenols, and other amines towards diphenyl diselenides with antimicrobial and antiviral properties ?

A reaction of bis[(2-chlorocarbonyl)phenyl] diselenide with various mono and bisnucleophiles such as aminophenols, phenols, and amines have been studied as a convenient general route to a series of new antimicrobial and antiviral diphenyl diselenides. The compounds, particularly bis[2-(hydroxyphenylcarbamoyl)]phenyl diselenides and reference benzisoselenazol-3(2H)-ones, exhibited high antimicrobial activity against Gram-positive bacterial species (Enterococcus spp., Staphylococcus spp.), and some compounds were also active against Gram-negative E. coli and fungi (Candida spp., A. Niger). The majority of compounds demonstrated high activity against human herpes virus type 1 (HHV-1) and moderate activity against encephalomyocarditis virus (EMCV), while they were generally inactive against vesicular stomatitis virus (VSV).

Benzisoselenazolones and process for the treatment of rheumatic and arthritic diseases using them

The present invention is related to new benzisoselenazolones having the general formula I STR1 new products having the general formula II STR2 used as intermediary products in the production of the compounds of formula I and a method for the treatment of rheumatic diseases using a compound of formula I as active agent.